Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Lazar (NPI 1225320666)

Field	Value
Entity Type	Individual
Organization	David Lazar
Address	945 82nd Pkwy
City	Myrtle Beach
State	SC
ZIP	29572
Taxonomy	Rheumatology Physician
NPI Enumerated	May 4, 2011

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

DAVID LAZAR is listed as a Rheumatology Physician based in MYRTLE BEACH, SC and has an NPI enumeration date of 2011-05-04 (~15 years ago), indicating over a decade of Medicaid/Medicare enrollment. His lifetime Medicare revenue on file is $2.7M, and there is no Medicaid billing on file.

Revenue is highly concentrated in a small number of biologic drug codes: the top 3 Medicare codes account for 82.3% of this provider's total Medicare revenue. Those top codes are J0129 ($1.3M revenue, 47.4% of Medicare revenue), J0717 ($534.4K revenue, 19.4%), and J1602 ($428.5K revenue, 15.5%).

The code mix indicates an in-office biologic/infusion service line: high-revenue HCPCS codes J0129 (abatacept), J0717 (certolizumab pegol), and J1602 (golimumab) are the dominant items billed, and administration/infusion CPTs such as 96401 (670 claims, $34.2K revenue) and 96365 (585 claims, $25.7K revenue) appear in the top codes, consistent with regular IV/subcutaneous biologic administration rather than a purely clinic visit model. This pattern suggests operational focus on drug infusion and on-site medication administration.

For J0129 this provider is a clear national outlier: J0129 shows 39.7K claims, $1.3M revenue (47.4% of Medicare revenue) and ranks #17 of 1221 providers nationally (99th percentile; extreme outlier). That ranking places the provider among the very highest-volume billers nationally for abatacept administration.

J0717 and J1602 are also important but less extreme: J0717 shows 133.6K claims and $534.4K revenue (19.4% of Medicare revenue) and ranks #83 of 848 providers nationally (90th percentile; typical, unremarkable volume), while J1602 shows 39K claims and $428.5K revenue (15.5% of Medicare revenue) and ranks #88 of 1041 providers nationally (92th percentile; typical, unremarkable volume). Together these two codes support substantial biologic throughput but do not exhibit the same extreme outlier status as J0129.

Non-drug evaluation-and-management activity is present but smaller by revenue: 99214 appears with 912 claims, $78.4K revenue (2.8% of Medicare revenue) and ranks #14400 of 479517 providers nationally (97th percentile; notably above typical national volume). This suggests the provider maintains a substantial established-patient office visit load in addition to infusion services, but those visits are a minority of total Medicare revenue.

Payer mix is effectively single-payer on file: total Medicare revenue is $2.7M while Medicaid billing is listed as none. The absence of Medicaid activity means revenue and utilization exposure is concentrated in Medicare reimbursement and drug-administration payments.

The operational and payment risk implications are concentrated in high-cost biologic administration: with the top 3 codes making up 82.3% of Medicare revenue and dominated by in-office injectable/infusible biologics, the practice’s revenue will be sensitive to changes in Medicare drug policy, site-of-care reimbursement, or shifts to physician-administered to pharmacy-dispensed models. The presence of multiple administration CPTs notably above typical national volume (for example 96401 ranks #169 of 3868, 96th percentile; 96365 ranks #281 of 8873, 97th percentile) reinforces that infusion services are core to this provider’s business model.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

32 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	39,650	$30	$1.3M
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	133,600	$1	$534.4K
J1602	Injection, golimumab, 1 mg, for intravenous use	38,960	$10	$428.5K
J3262	Injection, tocilizumab, 1 mg	55,900	$10	$279.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	910	$90	$78.4K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	670	$50	$34.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	310	$90	$27K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	590	$40	$25.7K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	50	$120	$6.3K
76881	In this procedure, the provider uses ultrasound to examine the complete joint for any defect or abnormality. The image appears in real time on a monitor, and a permanent image with interpretation is…	170	$40	$6.1K

Showing 1–10 of 32

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 32 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

David Lazar — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

32 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	1	40	9,640	$30	$424.2K
J0717	4	20	59,200	$1	$278.4K
J1602	9	40	23,560	$10	$264.5K
J3262	4	20	40,900	$1	$202.7K
99214	518	7,860	160	$80	$23.2K
96413	51	150	140	$90	$22.1K
99213	3,941	7,690	100	$60	$10.8K
90694	987	1,050	70	$80	$9.5K
96401	3	70	120	$50	$9.4K
99215	1,786	2,360	40	$120	$9.3K

Showing 1–10 of 32

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Lazar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Christopher Michaelis	SC	Emergency Medicine Physician	$3.3M	$0
Charles Degenhardt	GA	Rheumatology Physician	$2.4M	$0
David Chetrit	SC	Rheumatology Physician	$2.3M	$0
Rabih Nayfe	SC	Rheumatology Physician	$2M	$0
Gerald Larochelle	SC	Rheumatology Physician	$1.9M	$0
Donald Eagerton	SC	Endocrinology, Diabetes & Metabolism Physician	$734.8K	$0
Douglas Conaway	SC	Rheumatology Physician	$678.8K	$0
Chad Huberty	SC	Family Medicine Physician	$510.3K	$0
Lisa Mount	SC	Internal Medicine Physician	$444K	$0
Neil Trask	SC	Cardiovascular Disease Physician	$368.8K	$0

Nearby Providers

Other providers in the same ZIP code as David Lazar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Acs Primary Care Physicians - Southeast PC	SC	Emergency Medicine Physician	$0	$81.7M
Grand Strand Pediatrics & Adolescent Medicine, P.A.	SC	Pediatric Adolescent Medicine Physician	$0	$28M
Grand Strand Regional Medical Center LLC	SC	General Acute Care Hospital	$0	$27.4M
Carolina Regional Surgery Center. Ltd	SC	Ambulatory Surgical Clinic/Center	$3M	$1.7M
Coastal Carolina Primary Care, LLC	SC	Endocrinology, Diabetes & Metabolism Physician	$0	$4M
Brandon Coakley	SC	MOHS-Micrographic Surgery Physician	$3.5M	$0
Parkway Surgery Center	SC	Ambulatory Surgical Clinic/Center	$3.5M	$0
Jordan Henderson	SC	Hematology & Oncology Physician	$3.1M	$0
Dejuania Brown-rawls	SC	Hematology & Oncology Physician	$2.8M	$0
Stephen Hammond	SC	Dermatopathology Physician	$2.3M	$0

David Lazar — Billing Profile & Reimbursement Data

Sign up for David Lazar — Billing Profile & Reimbursement Data policy alerts

David Lazar — Billing Profile & Reimbursement Data

Sign up for David Lazar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References